BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma [Yahoo! Finance]
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma
BeOne Medicines (NASDAQ:ONC) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia